Medical.watch
@medicalwatch.bsky.social
Want practice changing updates in oncology/hematology? Get our weekly newsletter and join 2700+ clinicians.
Subscribe for free: Medical.watch
About us: https://tinyurl.com/Medicalwatch
Subscribe for free: Medical.watch
About us: https://tinyurl.com/Medicalwatch
Reposted by Medical.watch
💫🌟🔥 Hot off the press (Comments & Controversies)🌟💫
Thrilled to see the timely piece
👉 “Precision Oncology and Modernizing Evidence Standards”
🔑 Key takeaways:
🔵 RCT-only frameworks miss the reality of #PrecisionMedicine
🟢 Basket, umbrella & N-of-1 trials are cornerstones of #PrecisionOncology
Thrilled to see the timely piece
👉 “Precision Oncology and Modernizing Evidence Standards”
🔑 Key takeaways:
🔵 RCT-only frameworks miss the reality of #PrecisionMedicine
🟢 Basket, umbrella & N-of-1 trials are cornerstones of #PrecisionOncology
September 19, 2025 at 5:04 PM
💫🌟🔥 Hot off the press (Comments & Controversies)🌟💫
Thrilled to see the timely piece
👉 “Precision Oncology and Modernizing Evidence Standards”
🔑 Key takeaways:
🔵 RCT-only frameworks miss the reality of #PrecisionMedicine
🟢 Basket, umbrella & N-of-1 trials are cornerstones of #PrecisionOncology
Thrilled to see the timely piece
👉 “Precision Oncology and Modernizing Evidence Standards”
🔑 Key takeaways:
🔵 RCT-only frameworks miss the reality of #PrecisionMedicine
🟢 Basket, umbrella & N-of-1 trials are cornerstones of #PrecisionOncology
Reposted by Medical.watch
🚨 NEJM | Sept 2025
Low-dose aspirin in PI3K-altered localized #ColorectalCancer (ALASCCA)
“Low-dose aspirin cut 3-yr recurrence by ~50% in PI3K-altered localized colorectal cancer.”
www.nejm.org/doi/full/10....
Low-dose aspirin in PI3K-altered localized #ColorectalCancer (ALASCCA)
“Low-dose aspirin cut 3-yr recurrence by ~50% in PI3K-altered localized colorectal cancer.”
www.nejm.org/doi/full/10....
www.nejm.org
September 18, 2025 at 4:01 PM
🚨 NEJM | Sept 2025
Low-dose aspirin in PI3K-altered localized #ColorectalCancer (ALASCCA)
“Low-dose aspirin cut 3-yr recurrence by ~50% in PI3K-altered localized colorectal cancer.”
www.nejm.org/doi/full/10....
Low-dose aspirin in PI3K-altered localized #ColorectalCancer (ALASCCA)
“Low-dose aspirin cut 3-yr recurrence by ~50% in PI3K-altered localized colorectal cancer.”
www.nejm.org/doi/full/10....
Reposted by Medical.watch
💫🌟🎓🆕Immune activation & ICI-related fatigue
New study (JHU + Genentech)
✅ 58.5% of pts on ICIs reported fatigue
✅ Fatigue linked to ↑ Th1 cytokines (IFN-γ, IL-2, IL-12)
✅ Expansion of CD8+ effector T cells
✅ Fatigue = surrogate of immune activation
New study (JHU + Genentech)
✅ 58.5% of pts on ICIs reported fatigue
✅ Fatigue linked to ↑ Th1 cytokines (IFN-γ, IL-2, IL-12)
✅ Expansion of CD8+ effector T cells
✅ Fatigue = surrogate of immune activation
September 17, 2025 at 2:38 PM
💫🌟🎓🆕Immune activation & ICI-related fatigue
New study (JHU + Genentech)
✅ 58.5% of pts on ICIs reported fatigue
✅ Fatigue linked to ↑ Th1 cytokines (IFN-γ, IL-2, IL-12)
✅ Expansion of CD8+ effector T cells
✅ Fatigue = surrogate of immune activation
New study (JHU + Genentech)
✅ 58.5% of pts on ICIs reported fatigue
✅ Fatigue linked to ↑ Th1 cytokines (IFN-γ, IL-2, IL-12)
✅ Expansion of CD8+ effector T cells
✅ Fatigue = surrogate of immune activation
Reposted by Medical.watch
🧓👵 Geriatric assessment vs clinical evaluation in MM
J Geriatr Oncol (Sept 2025, Raddoux et al.)
👏 Congrats to the authors & to the #GeriOnc community advancing care for older #MM patients.
📊 Prospective study in 200 older adults w/ newly diagnosed #MultipleMyeloma
J Geriatr Oncol (Sept 2025, Raddoux et al.)
👏 Congrats to the authors & to the #GeriOnc community advancing care for older #MM patients.
📊 Prospective study in 200 older adults w/ newly diagnosed #MultipleMyeloma
September 16, 2025 at 4:34 PM
🧓👵 Geriatric assessment vs clinical evaluation in MM
J Geriatr Oncol (Sept 2025, Raddoux et al.)
👏 Congrats to the authors & to the #GeriOnc community advancing care for older #MM patients.
📊 Prospective study in 200 older adults w/ newly diagnosed #MultipleMyeloma
J Geriatr Oncol (Sept 2025, Raddoux et al.)
👏 Congrats to the authors & to the #GeriOnc community advancing care for older #MM patients.
📊 Prospective study in 200 older adults w/ newly diagnosed #MultipleMyeloma
Reposted by Medical.watch
🧠 Neurotoxicity in Cancer Therapy
New review (Nat Rev Clin Oncol)
✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity
✅ Clinical recognition & biomarkers
✅ Prevention & management strategies
🔍 Key messages – Cavaletti, Cámara, DeAngelis et al. Nat Rev Clin Oncol 2025
New review (Nat Rev Clin Oncol)
✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity
✅ Clinical recognition & biomarkers
✅ Prevention & management strategies
🔍 Key messages – Cavaletti, Cámara, DeAngelis et al. Nat Rev Clin Oncol 2025
September 15, 2025 at 2:36 PM
🧠 Neurotoxicity in Cancer Therapy
New review (Nat Rev Clin Oncol)
✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity
✅ Clinical recognition & biomarkers
✅ Prevention & management strategies
🔍 Key messages – Cavaletti, Cámara, DeAngelis et al. Nat Rev Clin Oncol 2025
New review (Nat Rev Clin Oncol)
✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity
✅ Clinical recognition & biomarkers
✅ Prevention & management strategies
🔍 Key messages – Cavaletti, Cámara, DeAngelis et al. Nat Rev Clin Oncol 2025
Reposted by Medical.watch
📑 New ESMO CPG on Lymphomas
✅ Updated dx & staging recs
✅ 1L & r/r treatment algorithms
✅ Integration of CAR-T, bispecifics & BTKis
www.annalsofoncology.org/article/S092...
✅ Updated dx & staging recs
✅ 1L & r/r treatment algorithms
✅ Integration of CAR-T, bispecifics & BTKis
www.annalsofoncology.org/article/S092...
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
The treatment landscape for many lymphoma entities continues to evolve rapidly, with
multiple recent approvals of novel non-chemotherapy (ChT)-based approaches. The following
Clinical Practice Guideli...
www.annalsofoncology.org
September 12, 2025 at 10:41 PM
📑 New ESMO CPG on Lymphomas
✅ Updated dx & staging recs
✅ 1L & r/r treatment algorithms
✅ Integration of CAR-T, bispecifics & BTKis
www.annalsofoncology.org/article/S092...
✅ Updated dx & staging recs
✅ 1L & r/r treatment algorithms
✅ Integration of CAR-T, bispecifics & BTKis
www.annalsofoncology.org/article/S092...
Reposted by Medical.watch
🌟🟠 HER2 in mCRC
New pooled analysis in JCO
(8 RCTs, n=1,604)🌟
✅ HER2+ = worse PFS & OS
❌ Not predictive for Bev vs anti-EGFR
➡️ Prognostic, not predictive
#GIOnc #ColorectalCancer #mCRC #HER2 #Oncology #JCO #Medicalwatch
ascopubs.org/doi/10.1200/...
New pooled analysis in JCO
(8 RCTs, n=1,604)🌟
✅ HER2+ = worse PFS & OS
❌ Not predictive for Bev vs anti-EGFR
➡️ Prognostic, not predictive
#GIOnc #ColorectalCancer #mCRC #HER2 #Oncology #JCO #Medicalwatch
ascopubs.org/doi/10.1200/...
ASCO Publications
ascopubs.org
September 11, 2025 at 3:14 PM
🌟🟠 HER2 in mCRC
New pooled analysis in JCO
(8 RCTs, n=1,604)🌟
✅ HER2+ = worse PFS & OS
❌ Not predictive for Bev vs anti-EGFR
➡️ Prognostic, not predictive
#GIOnc #ColorectalCancer #mCRC #HER2 #Oncology #JCO #Medicalwatch
ascopubs.org/doi/10.1200/...
New pooled analysis in JCO
(8 RCTs, n=1,604)🌟
✅ HER2+ = worse PFS & OS
❌ Not predictive for Bev vs anti-EGFR
➡️ Prognostic, not predictive
#GIOnc #ColorectalCancer #mCRC #HER2 #Oncology #JCO #Medicalwatch
ascopubs.org/doi/10.1200/...
Reposted by Medical.watch
🟢 Hepatocellular carcinoma (HCC) – 2025 global insights 🌍
New open-access review (Mauro, de Castro, Zeitlhoefler, Villanueva, Mazzaferro, Llovet et al.)
🔑 Highlights:
✅ 3rd leading cause of cancer death
✅ Etiology shift → viral ↓ | ALD & MASLD ↑
✅ Prevention: HBV vax + antivirals effective
New open-access review (Mauro, de Castro, Zeitlhoefler, Villanueva, Mazzaferro, Llovet et al.)
🔑 Highlights:
✅ 3rd leading cause of cancer death
✅ Etiology shift → viral ↓ | ALD & MASLD ↑
✅ Prevention: HBV vax + antivirals effective
September 10, 2025 at 9:39 PM
🟢 Hepatocellular carcinoma (HCC) – 2025 global insights 🌍
New open-access review (Mauro, de Castro, Zeitlhoefler, Villanueva, Mazzaferro, Llovet et al.)
🔑 Highlights:
✅ 3rd leading cause of cancer death
✅ Etiology shift → viral ↓ | ALD & MASLD ↑
✅ Prevention: HBV vax + antivirals effective
New open-access review (Mauro, de Castro, Zeitlhoefler, Villanueva, Mazzaferro, Llovet et al.)
🔑 Highlights:
✅ 3rd leading cause of cancer death
✅ Etiology shift → viral ↓ | ALD & MASLD ↑
✅ Prevention: HBV vax + antivirals effective
Reposted by Medical.watch
📢 European Journal of Cancer – New Research
Cost-effectiveness of perioperative Durvalumab + Gem/Cis in MIBC (Germany)
📊 Results:
➡️ Cost: €113,224 (SoC) → €126,386 (+€13,162)
➡️ QALYs: 3.16 → 3.37 (+0.21)
➡️ ICER: €61,006/QALY
➡️ WTP €100,000 → 76.5% probability of cost-effectiveness
Cost-effectiveness of perioperative Durvalumab + Gem/Cis in MIBC (Germany)
📊 Results:
➡️ Cost: €113,224 (SoC) → €126,386 (+€13,162)
➡️ QALYs: 3.16 → 3.37 (+0.21)
➡️ ICER: €61,006/QALY
➡️ WTP €100,000 → 76.5% probability of cost-effectiveness
September 9, 2025 at 4:33 PM
📢 European Journal of Cancer – New Research
Cost-effectiveness of perioperative Durvalumab + Gem/Cis in MIBC (Germany)
📊 Results:
➡️ Cost: €113,224 (SoC) → €126,386 (+€13,162)
➡️ QALYs: 3.16 → 3.37 (+0.21)
➡️ ICER: €61,006/QALY
➡️ WTP €100,000 → 76.5% probability of cost-effectiveness
Cost-effectiveness of perioperative Durvalumab + Gem/Cis in MIBC (Germany)
📊 Results:
➡️ Cost: €113,224 (SoC) → €126,386 (+€13,162)
➡️ QALYs: 3.16 → 3.37 (+0.21)
➡️ ICER: €61,006/QALY
➡️ WTP €100,000 → 76.5% probability of cost-effectiveness
Reposted by Medical.watch
🌍 #MWGlobalOnc
Prognosis & biology of ER-low metastatic breast cancer – TONIC & multicenter cohort
🔑 Key Messages:
✅ ER-low (1–9%) behaves biologically closer to TNBC than ER+/HER2−
✅ Worse OS vs ER+/HER2−; prognosis similar to TNBC
✅ Phenotypic switch from ER+ → ER-low at relapse = poor outcomes
Prognosis & biology of ER-low metastatic breast cancer – TONIC & multicenter cohort
🔑 Key Messages:
✅ ER-low (1–9%) behaves biologically closer to TNBC than ER+/HER2−
✅ Worse OS vs ER+/HER2−; prognosis similar to TNBC
✅ Phenotypic switch from ER+ → ER-low at relapse = poor outcomes
September 8, 2025 at 2:55 PM
🌍 #MWGlobalOnc
Prognosis & biology of ER-low metastatic breast cancer – TONIC & multicenter cohort
🔑 Key Messages:
✅ ER-low (1–9%) behaves biologically closer to TNBC than ER+/HER2−
✅ Worse OS vs ER+/HER2−; prognosis similar to TNBC
✅ Phenotypic switch from ER+ → ER-low at relapse = poor outcomes
Prognosis & biology of ER-low metastatic breast cancer – TONIC & multicenter cohort
🔑 Key Messages:
✅ ER-low (1–9%) behaves biologically closer to TNBC than ER+/HER2−
✅ Worse OS vs ER+/HER2−; prognosis similar to TNBC
✅ Phenotypic switch from ER+ → ER-low at relapse = poor outcomes
Reposted by Medical.watch
✅ Barriers: resource gaps, training, access in LMICs
➡️ Clinical practice impact: GA should be mandatory in global oncology to optimize outcomes for older adults.
#GeriatricOncology #ASCO #OncoTwitter #Medicalwatch #CancerCare #GlobalOncology
ascopubs.org/doi/10.1200/...
➡️ Clinical practice impact: GA should be mandatory in global oncology to optimize outcomes for older adults.
#GeriatricOncology #ASCO #OncoTwitter #Medicalwatch #CancerCare #GlobalOncology
ascopubs.org/doi/10.1200/...
Geriatric Assessment: ASCO Global Guideline | JCO Global Oncology
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual, ASCO Guidelines follow ...
ascopubs.org
September 5, 2025 at 8:05 PM
✅ Barriers: resource gaps, training, access in LMICs
➡️ Clinical practice impact: GA should be mandatory in global oncology to optimize outcomes for older adults.
#GeriatricOncology #ASCO #OncoTwitter #Medicalwatch #CancerCare #GlobalOncology
ascopubs.org/doi/10.1200/...
➡️ Clinical practice impact: GA should be mandatory in global oncology to optimize outcomes for older adults.
#GeriatricOncology #ASCO #OncoTwitter #Medicalwatch #CancerCare #GlobalOncology
ascopubs.org/doi/10.1200/...
Reposted by Medical.watch
Heading to an appointment this weekend? Plan ahead for street closures 🚧 👷 Aloha St. will be closed at Fairview Ave. N. from 7 p.m. Friday, 9/5 until 6 a.m. Monday, 9/8. This is part of the City of Seattle’s RapidRide J-Line construction project. bit.ly/47GyDV0
September 4, 2025 at 5:27 PM
Heading to an appointment this weekend? Plan ahead for street closures 🚧 👷 Aloha St. will be closed at Fairview Ave. N. from 7 p.m. Friday, 9/5 until 6 a.m. Monday, 9/8. This is part of the City of Seattle’s RapidRide J-Line construction project. bit.ly/47GyDV0
Reposted by Medical.watch
🎥 #MWVisualAbstract
Surgical complexity after NACT in primary ovarian cancer
✍️ Chiara Ainio, Marina Rosanu, Lucia Ribero, Amanda L. Tapia, Giovanni D. Aletti, William A. Cliby et al.
🔶 Key Messages:
➡️ >50% of pts undergoing IDS after NACT required advanced procedures
Surgical complexity after NACT in primary ovarian cancer
✍️ Chiara Ainio, Marina Rosanu, Lucia Ribero, Amanda L. Tapia, Giovanni D. Aletti, William A. Cliby et al.
🔶 Key Messages:
➡️ >50% of pts undergoing IDS after NACT required advanced procedures
September 4, 2025 at 5:26 PM
🎥 #MWVisualAbstract
Surgical complexity after NACT in primary ovarian cancer
✍️ Chiara Ainio, Marina Rosanu, Lucia Ribero, Amanda L. Tapia, Giovanni D. Aletti, William A. Cliby et al.
🔶 Key Messages:
➡️ >50% of pts undergoing IDS after NACT required advanced procedures
Surgical complexity after NACT in primary ovarian cancer
✍️ Chiara Ainio, Marina Rosanu, Lucia Ribero, Amanda L. Tapia, Giovanni D. Aletti, William A. Cliby et al.
🔶 Key Messages:
➡️ >50% of pts undergoing IDS after NACT required advanced procedures
Reposted by Medical.watch
💡 #MWClinicalTips
FGFR1-amplified colorectal cancer: a distinct prognostic subtype
✅ Large-scale profiling (n=7606) → FGFR1 amplification = predominant FGFR alteration in CRC (≈4%).
✨ Independent marker of poor prognosis: ↓DFS (HR 2.91) & ↓PFS (HR 2.52).
FGFR1-amplified colorectal cancer: a distinct prognostic subtype
✅ Large-scale profiling (n=7606) → FGFR1 amplification = predominant FGFR alteration in CRC (≈4%).
✨ Independent marker of poor prognosis: ↓DFS (HR 2.91) & ↓PFS (HR 2.52).
September 3, 2025 at 5:47 PM
💡 #MWClinicalTips
FGFR1-amplified colorectal cancer: a distinct prognostic subtype
✅ Large-scale profiling (n=7606) → FGFR1 amplification = predominant FGFR alteration in CRC (≈4%).
✨ Independent marker of poor prognosis: ↓DFS (HR 2.91) & ↓PFS (HR 2.52).
FGFR1-amplified colorectal cancer: a distinct prognostic subtype
✅ Large-scale profiling (n=7606) → FGFR1 amplification = predominant FGFR alteration in CRC (≈4%).
✨ Independent marker of poor prognosis: ↓DFS (HR 2.91) & ↓PFS (HR 2.52).
Reposted by Medical.watch
#COTipTuesday
🔵 Prostate Cancer Statistics 2025 – CA Cancer J Clin
✅ 313,780 new cases & 35,770 deaths expected in US (2025)
✅ Incidence ↑ 3%/yr since 2014, driven by advanced-stage dx
✅ Distant-stage PCa rising across all ages 📈
✅ Black men: 67% ↑ incidence & ~2x mortality vs White men
🔵 Prostate Cancer Statistics 2025 – CA Cancer J Clin
✅ 313,780 new cases & 35,770 deaths expected in US (2025)
✅ Incidence ↑ 3%/yr since 2014, driven by advanced-stage dx
✅ Distant-stage PCa rising across all ages 📈
✅ Black men: 67% ↑ incidence & ~2x mortality vs White men
September 2, 2025 at 4:29 PM
#COTipTuesday
🔵 Prostate Cancer Statistics 2025 – CA Cancer J Clin
✅ 313,780 new cases & 35,770 deaths expected in US (2025)
✅ Incidence ↑ 3%/yr since 2014, driven by advanced-stage dx
✅ Distant-stage PCa rising across all ages 📈
✅ Black men: 67% ↑ incidence & ~2x mortality vs White men
🔵 Prostate Cancer Statistics 2025 – CA Cancer J Clin
✅ 313,780 new cases & 35,770 deaths expected in US (2025)
✅ Incidence ↑ 3%/yr since 2014, driven by advanced-stage dx
✅ Distant-stage PCa rising across all ages 📈
✅ Black men: 67% ↑ incidence & ~2x mortality vs White men
Reposted by Medical.watch
🟢 Circulating KIM-1 in adjuvant #RCC
New Annals of Oncology analysis (IMmotion010):
✅ Elevated post-nephrectomy plasma KIM-1 = ↑ recurrence risk (HR 1.68)
✅ KIM-1high pts benefited from adjuvant atezo (HR 0.72)
New Annals of Oncology analysis (IMmotion010):
✅ Elevated post-nephrectomy plasma KIM-1 = ↑ recurrence risk (HR 1.68)
✅ KIM-1high pts benefited from adjuvant atezo (HR 0.72)
September 1, 2025 at 11:51 PM
🟢 Circulating KIM-1 in adjuvant #RCC
New Annals of Oncology analysis (IMmotion010):
✅ Elevated post-nephrectomy plasma KIM-1 = ↑ recurrence risk (HR 1.68)
✅ KIM-1high pts benefited from adjuvant atezo (HR 0.72)
New Annals of Oncology analysis (IMmotion010):
✅ Elevated post-nephrectomy plasma KIM-1 = ↑ recurrence risk (HR 1.68)
✅ KIM-1high pts benefited from adjuvant atezo (HR 0.72)
Reposted by Medical.watch
🌟🫁 Early & locally advanced #NSCLC – New
@myESMO
Guidelines🌟
✅ Screening: LD-CT for heavy smokers (55–74y)
✅ Biomarkers: EGFR, ALK & PD-L1 testing essential
✅ Surgery: Sublobar resection ≈ lobectomy for ≤2cm tumors
@myESMO
Guidelines🌟
✅ Screening: LD-CT for heavy smokers (55–74y)
✅ Biomarkers: EGFR, ALK & PD-L1 testing essential
✅ Surgery: Sublobar resection ≈ lobectomy for ≤2cm tumors
August 29, 2025 at 2:49 PM
🌟🫁 Early & locally advanced #NSCLC – New
@myESMO
Guidelines🌟
✅ Screening: LD-CT for heavy smokers (55–74y)
✅ Biomarkers: EGFR, ALK & PD-L1 testing essential
✅ Surgery: Sublobar resection ≈ lobectomy for ≤2cm tumors
@myESMO
Guidelines🌟
✅ Screening: LD-CT for heavy smokers (55–74y)
✅ Biomarkers: EGFR, ALK & PD-L1 testing essential
✅ Surgery: Sublobar resection ≈ lobectomy for ≤2cm tumors
Reposted by Medical.watch
🌟🧠 #MWThinkWednesday
Geriatric Assessment: ASCO Global Guideline 🌟
✅ GA is recommended for all adults ≥65 receiving cancer treatment
✨ Identifies vulnerabilities beyond chronological age (function, comorbidities, polypharmacy, nutrition, cognition, psychosocial health)
Geriatric Assessment: ASCO Global Guideline 🌟
✅ GA is recommended for all adults ≥65 receiving cancer treatment
✨ Identifies vulnerabilities beyond chronological age (function, comorbidities, polypharmacy, nutrition, cognition, psychosocial health)
August 28, 2025 at 2:33 PM
🌟🧠 #MWThinkWednesday
Geriatric Assessment: ASCO Global Guideline 🌟
✅ GA is recommended for all adults ≥65 receiving cancer treatment
✨ Identifies vulnerabilities beyond chronological age (function, comorbidities, polypharmacy, nutrition, cognition, psychosocial health)
Geriatric Assessment: ASCO Global Guideline 🌟
✅ GA is recommended for all adults ≥65 receiving cancer treatment
✨ Identifies vulnerabilities beyond chronological age (function, comorbidities, polypharmacy, nutrition, cognition, psychosocial health)
Reposted by Medical.watch
🧠 #MWThinkWednesday
Inferior control arms in oncology trials in LMICs: contextualised or compromised?
✅ Some oncology trials in LMICs still use inferior control arms vs HIC standards.
✅ Raises ethical concerns: are we contextualizing care or compromising patients?
Inferior control arms in oncology trials in LMICs: contextualised or compromised?
✅ Some oncology trials in LMICs still use inferior control arms vs HIC standards.
✅ Raises ethical concerns: are we contextualizing care or compromising patients?
August 27, 2025 at 2:43 PM
🧠 #MWThinkWednesday
Inferior control arms in oncology trials in LMICs: contextualised or compromised?
✅ Some oncology trials in LMICs still use inferior control arms vs HIC standards.
✅ Raises ethical concerns: are we contextualizing care or compromising patients?
Inferior control arms in oncology trials in LMICs: contextualised or compromised?
✅ Some oncology trials in LMICs still use inferior control arms vs HIC standards.
✅ Raises ethical concerns: are we contextualizing care or compromising patients?
Reposted by Medical.watch
💡 #MWClinicalTips
Brain imaging screening in metastatic breast cancer: patients’ & physicians’ perspectives
✅ 529 physicians (50 countries): 65% request BIS in asymptomatic MBC, mainly for HER2+ & TNBC
Brain imaging screening in metastatic breast cancer: patients’ & physicians’ perspectives
✅ 529 physicians (50 countries): 65% request BIS in asymptomatic MBC, mainly for HER2+ & TNBC
August 26, 2025 at 2:44 PM
💡 #MWClinicalTips
Brain imaging screening in metastatic breast cancer: patients’ & physicians’ perspectives
✅ 529 physicians (50 countries): 65% request BIS in asymptomatic MBC, mainly for HER2+ & TNBC
Brain imaging screening in metastatic breast cancer: patients’ & physicians’ perspectives
✅ 529 physicians (50 countries): 65% request BIS in asymptomatic MBC, mainly for HER2+ & TNBC
Reposted by Medical.watch
🌍 #MWGlobalOnc
Artificial intelligence across the cancer care continuum
✅ AI transforms oncology from prevention → survivorship → end-of-life care
✨ Early detection: deep learning predicts pancreatic & lung cancer risk yrs before diagnosis
Artificial intelligence across the cancer care continuum
✅ AI transforms oncology from prevention → survivorship → end-of-life care
✨ Early detection: deep learning predicts pancreatic & lung cancer risk yrs before diagnosis
August 25, 2025 at 2:57 PM
🌍 #MWGlobalOnc
Artificial intelligence across the cancer care continuum
✅ AI transforms oncology from prevention → survivorship → end-of-life care
✨ Early detection: deep learning predicts pancreatic & lung cancer risk yrs before diagnosis
Artificial intelligence across the cancer care continuum
✅ AI transforms oncology from prevention → survivorship → end-of-life care
✨ Early detection: deep learning predicts pancreatic & lung cancer risk yrs before diagnosis
Reposted by Medical.watch
🌟🚀 Novel trial designs in the era of molecular oncology🌟
🔑 Key insights:
✅ Molecular reclassification is reshaping cancer trial paradigms
✅ Basket & umbrella designs accelerate drug development across tumor types
✅ Adaptive, platform & seamless trials enable faster, more efficient testing
🔑 Key insights:
✅ Molecular reclassification is reshaping cancer trial paradigms
✅ Basket & umbrella designs accelerate drug development across tumor types
✅ Adaptive, platform & seamless trials enable faster, more efficient testing
August 22, 2025 at 2:54 PM
🌟🚀 Novel trial designs in the era of molecular oncology🌟
🔑 Key insights:
✅ Molecular reclassification is reshaping cancer trial paradigms
✅ Basket & umbrella designs accelerate drug development across tumor types
✅ Adaptive, platform & seamless trials enable faster, more efficient testing
🔑 Key insights:
✅ Molecular reclassification is reshaping cancer trial paradigms
✅ Basket & umbrella designs accelerate drug development across tumor types
✅ Adaptive, platform & seamless trials enable faster, more efficient testing
Reposted by Medical.watch
🧬 New AML care update for unfit patients
Ven + HMA = current backbone ⚡️
CR/CRi ~40–90%, 3-yr OS up to 67% 📈 (better w/ NPM1, IDH2; worse w/ TP53, FLT3-ITD)
Future: refine triplets ➕ optimize dosing, ASCT timing, & add PROs 🗣️
www.nature.com/articles/s41...
Ven + HMA = current backbone ⚡️
CR/CRi ~40–90%, 3-yr OS up to 67% 📈 (better w/ NPM1, IDH2; worse w/ TP53, FLT3-ITD)
Future: refine triplets ➕ optimize dosing, ASCT timing, & add PROs 🗣️
www.nature.com/articles/s41...
Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms - Blood Cancer Journal
Blood Cancer Journal - Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms
www.nature.com
August 21, 2025 at 9:05 PM
🧬 New AML care update for unfit patients
Ven + HMA = current backbone ⚡️
CR/CRi ~40–90%, 3-yr OS up to 67% 📈 (better w/ NPM1, IDH2; worse w/ TP53, FLT3-ITD)
Future: refine triplets ➕ optimize dosing, ASCT timing, & add PROs 🗣️
www.nature.com/articles/s41...
Ven + HMA = current backbone ⚡️
CR/CRi ~40–90%, 3-yr OS up to 67% 📈 (better w/ NPM1, IDH2; worse w/ TP53, FLT3-ITD)
Future: refine triplets ➕ optimize dosing, ASCT timing, & add PROs 🗣️
www.nature.com/articles/s41...
Reposted by Medical.watch
💡 #MWClinicalTips
📢 Advances in Neuroendocrine Tumors (NETs) — therapeutic landscape update
✅ NETs are highly heterogeneous — site of origin & biology determine management.
✅ Somatostatin analogs remain backbone for symptom & tumor control.
📢 Advances in Neuroendocrine Tumors (NETs) — therapeutic landscape update
✅ NETs are highly heterogeneous — site of origin & biology determine management.
✅ Somatostatin analogs remain backbone for symptom & tumor control.
August 20, 2025 at 2:43 PM
💡 #MWClinicalTips
📢 Advances in Neuroendocrine Tumors (NETs) — therapeutic landscape update
✅ NETs are highly heterogeneous — site of origin & biology determine management.
✅ Somatostatin analogs remain backbone for symptom & tumor control.
📢 Advances in Neuroendocrine Tumors (NETs) — therapeutic landscape update
✅ NETs are highly heterogeneous — site of origin & biology determine management.
✅ Somatostatin analogs remain backbone for symptom & tumor control.
Reposted by Medical.watch
💡 #MWClinicalTips
📢 IMvigor011 trial: ctDNA-guided adjuvant immunotherapy in MIBC. Natera & Genentech/Roche
✅ Signatera-positive pts + atezolizumab → significant ↑ DFS & OS
✅ Signatera-negative pts → excellent outcomes w/out adjuvant Rx
📢 IMvigor011 trial: ctDNA-guided adjuvant immunotherapy in MIBC. Natera & Genentech/Roche
✅ Signatera-positive pts + atezolizumab → significant ↑ DFS & OS
✅ Signatera-negative pts → excellent outcomes w/out adjuvant Rx
August 19, 2025 at 2:33 PM
💡 #MWClinicalTips
📢 IMvigor011 trial: ctDNA-guided adjuvant immunotherapy in MIBC. Natera & Genentech/Roche
✅ Signatera-positive pts + atezolizumab → significant ↑ DFS & OS
✅ Signatera-negative pts → excellent outcomes w/out adjuvant Rx
📢 IMvigor011 trial: ctDNA-guided adjuvant immunotherapy in MIBC. Natera & Genentech/Roche
✅ Signatera-positive pts + atezolizumab → significant ↑ DFS & OS
✅ Signatera-negative pts → excellent outcomes w/out adjuvant Rx